The online version of this article (https://doi.org/10.1186/s12885-017-3644-3) contains supplementary material, which is available to authorized users.
Clinical trials are necessary for the advancement of cancer treatment and care, however low rates of participation in such trials limit the generalisability of findings. The objective of this study was to examine the proportion of medical oncology outpatients in Australia who are invited and consent to participate in clinical trials and the factors associated with this.
A sample of adult medical oncology patients was recruited from three Australian cancer treatment centres. Consenting patients completed two paper-and-pencil surveys; one at the time of consent and another approximately 1 month later. A multivariate logistic regression was conducted to explore factors associated with invitation and participation in a trial.
Thirty-eight percent (n = 146) of the 383 participants reported they had been invited to take part in a clinical trial. Of those invited, 93% reported consenting to participate in the trial, with the majority indicating that they did not regret their decision (89%). Treatment centre and time since diagnosis were significantly associated with being invited to take part in a clinical trial. None of the factors examined were associated with clinical trial consent rates.
The main barrier to clinical trial participation is not being invited to do so, with the centre the patient attends being a modifiable determinant of whether or not they are invited. Increasing the resources available to treatment centres to ensure all patients are offered participation in trials they are eligible for may help to improve rates of trial participation.
Additional file 1: Clinical Trials Questionnaire. Participation in Clinical Trials: Questionnaire items assessing participation in clinical trials, views regarding trial participation, and views regarding participation in multiple trials. (PDF 267 kb)12885_2017_3644_MOESM1_ESM.pdf
Education Network to Advance Cancer Clinical Trials. Five Steps to Enhance Patient Participation in Cancer Clinical Trials: Guide and Workbook. In .: ENACCT; 2011.
Clinical Oncological Society of Australia, Cancer Council Australia, National Cancer Control Initiative: Optimising cancer care in Australia. In . Melbourne: National Cancer Control Initiative; 2002.
Murray P, Kerridge I, Tiley C, Catanzariti A, Welberry H, Lean C, Sinclair S, Bishop J, Bradstock K. Enrolment of patients to clinical trials in haematological cancer in new South Wales: current status, perceived barriers and opportunities for improvement. Intern Med J. 2010;40(2):133–8. CrossRefPubMed
Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington: National Academies Press; 2010.
SAS Institute. SAS v9.4. Cary, North Carolina: SAS Institute; 2013.
Australian Institute of Health and Welfare. Cancer in Australia: an overview 2014. In: Cancer series no 90 cat no CAN 88. Canberra: AIHW; 2014.
Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P. Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Cancer Netw. 2007;5(8):753–62. CrossRef
McMahon VA, Matthews S, Capper H, Chudleigh JB, McLachlan CS. Understanding decision and enabling factors influencing clinical trial participation in Australia: a view point. Asian Pac J Cancer Prev. 2011;12(11):3153–6. PubMed
- Access to clinical trials among oncology patients: results of a cross sectional survey
Allison W. Boyes
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II